IBIO
Price
$0.71
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
12.15M
STOK
Price
$11.63
Change
-$0.21 (-1.77%)
Updated
Jun 27 closing price
Capitalization
634.42M
43 days until earnings call
Interact to see
Advertisement

IBIO vs STOK

Header iconIBIO vs STOK Comparison
Open Charts IBIO vs STOKBanner chart's image
iBio
Price$0.71
Change-$0.00 (-0.00%)
Volume$159.04K
Capitalization12.15M
Stoke Therapeutics
Price$11.63
Change-$0.21 (-1.77%)
Volume$1.37M
Capitalization634.42M
IBIO vs STOK Comparison Chart in %
Loading...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBIO vs. STOK commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Hold and STOK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (IBIO: $0.71 vs. STOK: $11.63)
Brand notoriety: IBIO and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 5% vs. STOK: 213%
Market capitalization -- IBIO: $12.15M vs. STOK: $634.42M
IBIO [@Biotechnology] is valued at $12.15M. STOK’s [@Biotechnology] market capitalization is $634.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 1 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • IBIO’s FA Score: 1 green, 4 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 2 bullish TA indicator(s).

  • IBIO’s TA Score: 4 bullish, 4 bearish.
  • STOK’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, IBIO is a better buy in the short-term than STOK.

Price Growth

IBIO (@Biotechnology) experienced а -7.91% price change this week, while STOK (@Biotechnology) price change was +0.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

STOK is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($634M) has a higher market cap than IBIO($12.1M). STOK has higher P/E ratio than IBIO: STOK (14.17) vs IBIO (0.65). STOK YTD gains are higher at: 5.440 vs. IBIO (-71.020). STOK has higher annual earnings (EBITDA): 40.3M vs. IBIO (-15.11M). STOK has more cash in the bank: 357M vs. IBIO (4.96M). STOK has less debt than IBIO: STOK (2.35M) vs IBIO (3.76M). STOK has higher revenues than IBIO: STOK (191M) vs IBIO (375K).
IBIOSTOKIBIO / STOK
Capitalization12.1M634M2%
EBITDA-15.11M40.3M-37%
Gain YTD-71.0205.440-1,306%
P/E Ratio0.6514.175%
Revenue375K191M0%
Total Cash4.96M357M1%
Total Debt3.76M2.35M160%
FUNDAMENTALS RATINGS
IBIO vs STOK: Fundamental Ratings
IBIO
STOK
OUTLOOK RATING
1..100
9583
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9841
PRICE GROWTH RATING
1..100
9639
P/E GROWTH RATING
1..100
9829
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBIO's Valuation (27) in the Biotechnology industry is in the same range as STOK (53) in the null industry. This means that IBIO’s stock grew similarly to STOK’s over the last 12 months.

IBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STOK (100) in the null industry. This means that IBIO’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (41) in the null industry is somewhat better than the same rating for IBIO (98) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than IBIO’s over the last 12 months.

STOK's Price Growth Rating (39) in the null industry is somewhat better than the same rating for IBIO (96) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than IBIO’s over the last 12 months.

STOK's P/E Growth Rating (29) in the null industry is significantly better than the same rating for IBIO (98) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than IBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIOSTOK
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 18 days ago
79%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 12 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VMEO4.01-0.05
-1.23%
Vimeo
CCJ73.26-1.20
-1.61%
Cameco Corp
PHGE0.44-0.01
-2.22%
BiomX Inc
OR25.03-0.69
-2.68%
OR Royalties Inc.
STKS4.16-0.30
-6.63%
ONE Group Hospitality (The)

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with REPL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
N/A
REPL - IBIO
38%
Loosely correlated
N/A
LIANY - IBIO
37%
Loosely correlated
+1.18%
NUVB - IBIO
36%
Loosely correlated
-2.54%
LENZ - IBIO
35%
Loosely correlated
+0.23%
STOK - IBIO
31%
Poorly correlated
-1.77%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-1.77%
IDYA - STOK
53%
Loosely correlated
-4.13%
IMNM - STOK
52%
Loosely correlated
-0.23%
DNLI - STOK
51%
Loosely correlated
-2.69%
RNA - STOK
50%
Loosely correlated
-2.68%
QTTB - STOK
49%
Loosely correlated
-5.16%
More